Handelsavisen
prelaunch
Companies Healthcare BALM4.SA
BA
BALM4.SA B3 (São Paulo) Medical Equipment, Supplies & Distribution

Baumer SA

$26,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
26,26 %
Op margin
11,7 %
ROE
2,7 %
Net margin
11,1 %
Debt / equity
0,13
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Baumer SA is a medical equipment and supplies company that generates revenue through the distribution and sale of healthcare products and services.

Business. Baumer SA (BALM4.SA) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Baumer SA is headquartered in Brazil and is listed on the B3 (São Paulo) stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
2,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BALM4.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BALM4.SA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Baumer SA (BALM4.SA) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Baumer SA is headquartered in Brazil and is listed on the B3 (São Paulo) stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Baumer SA maintains a conservative capital structure with a debt-to-equity ratio of 0.13, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 2.86, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's free cash flow is negative at -506,000 BRL, and its net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    In terms of profitability, Baumer SA's return on equity (ROE) is 2.7%, and its return on assets (ROA) is 1.58%. These figures are below the typical thresholds for high-performing healthcare equipment firms, indicating that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 4,264,000 BRL on revenue of 36,320,000 BRL, is 11.74%, which is in line with the industry's median but not exceptional.

    The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration risk. However, the lack of segmentation data suggests that the company may have a relatively undiversified revenue base, which could expose it to regional or product-specific risks.

    Looking ahead, the company's growth trajectory is not clearly defined in the available data. The absence of specific revenue growth projections or historical growth rates makes it difficult to assess the company's future performance. The capital expenditure of -2,649,000 BRL indicates that the company is investing in its operations, but the negative free cash flow suggests that these investments are not yet generating positive cash returns.

    The risk assessment for Baumer SA highlights a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent threat of share dilution. However, the negative free cash flow and the negative net cash position after debt suggest that the company may need to raise additional capital in the near term, which could introduce new risks.

    There are no recent events or filings mentioned in the available data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests that the company may not be actively communicating with investors or disclosing material developments.

    Key takeaways
    • Baumer SA has a conservative capital structure with a low debt-to-equity ratio of 0.13.
    • The company's return on equity (2.7%) and return on assets (1.58%) are below typical thresholds for high-performing healthcare equipment firms.
    • The company's liquidity position is characterized as medium risk, with a current ratio of 2.86.
    • The company's free cash flow is negative at -506,000 BRL, and its net cash position is negative after subtracting total debt.
    • The company's growth trajectory is not clearly defined in the available data.
    • The company has a low dilution risk, with no imminent threat of share dilution.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Baumer generated BRL 213.7 million in FY0 revenue, reflecting a strong 12.4% four-year compound annual growth rate.

    Baumer's 11.7% operating margin vastly outperforms the 3.1% cohort median, demonstrating superior operational efficiency.

    With a debt-to-equity ratio of 0.13, Baumer maintains a conservative leverage profile below the 0.20 cohort median.

    The firm exhibits low dilution and credit risk flags, suggesting a stable capital structure and limited downside threats.

    BEAR CASE · 3

    Return on equity stands at a low 2.7%, indicating inefficient use of shareholder capital despite high margins.

    Operating income fell 3.6% year-over-year to BRL 34.7 million, showing stagnation in core operational earnings.

    The company faces medium liquidity risk, which could constrain its ability to manage short-term financial obligations.

    In focus — financials by report

    Valuation FY

    Market price
    $26,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $149.9M
    Net cash
    -$4.3M
    Current ratio
    2.9
    Debt / equity
    0.1
    ROA
    1.6%
    ROE
    2.7%
    Cash conversion
    137.0%
    CapEx / revenue
    -7.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin11,7 %Above median
    Net Margin11,1 %Above median
    ROE2,7 %Above median
    Capex / Rev-7,3 %Below median
    D/E0,13Above median
    Cash Conv1,37Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Baumer SA Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BALM4.SACanonical
    B3 (São Paulo) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage